Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming

Xu,Huadan; He,Yichun; Ma,Jiaoyan; Zhao,Yuanxin; Liu,Yanan; Sun,Liankun; Su,Jing

doi:10.3892/ijo.2020.5098

Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming

Authors:
- Huadan Xu
- Yichun He
- Jiaoyan Ma
- Yuanxin Zhao
- Yanan Liu
- Liankun Sun
- Jing Su
View Affiliations

Affiliations: Key Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Neurosurgery, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: July 10, 2020 https://doi.org/10.3892/ijo.2020.5098
Pages: 733-742
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Warburg effect is a unique metabolic feature of the majority of tumor cells and is closely related to chemotherapeutic resistance. Pyruvate dehydrogenase kinase 1 (PDK1) is considered a ‘switch’ that controls the fate of pyruvate in glucose metabolism. However, to date, to the best of our knowledge, there are only a few studies to available which had studied the reduction of chemotherapeutic resistance via the metabolic reprogramming of tumor cells with PDK1 as a target. In the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen species ROS (mtROS) and a decrease in mitochondrial membrane potential (MMP), thereby increasing the apoptosis induced by oxaliplatin (OXA). Furthermore, the present study elucidated that the targeting of PDK1 may be a potential strategy for targeting metabolism in the chemotherapy of HCC. In addition, DIC as an ‘old drug’ exhibits novel efficacy, bringing new hope for antitumor therapy.

View Figures

View References

1	Wallace MC, Preen D, Jeffrey GP and Adams LA: The evolving epidemiology of hepatocellular carcinoma: A global perspective. Expert Rev Gastroenterol Hepatol. 9:765–779. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M, Takahashi-Yanaga F, Sasaguri T, Sekimoto M, Matsuura N, et al: Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci. 99:129–139. 2008.
3	Abdel-Rahman O: Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma. Curr Oncol Rep. 16:3942014. View Article : Google Scholar : PubMed/NCBI
4	Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, Yin L, Han Y, Cai C, Li Y, et al: BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma. Cancer Lett. 411:117–129. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yin X, Tang B, Li JH, Wang Y, Zhang L, Xie XY, Zhang BH, Qiu SJ, Wu WZ and Ren ZG: ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. J Exp Clin Cancer Res. 36:1662017. View Article : Google Scholar : PubMed/NCBI
6	Sheng J, Shen L, Sun L, Zhang X, Cui R and Wang L: Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondriallysosomal crosstalk. Cell Prolif. 52:e126092019. View Article : Google Scholar
7	Morandi A and Indraccolo S: Linking metabolic reprogramming to therapy resistance in cancer. Biochim Biophys Acta Rev Cancer. 1868:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
8	Fekir K, Dubois-Pot-Schneider H, Désert R, Daniel Y, Glaise D, Rauch C, Morel F, Fromenty B, Musso O, Cabillic F, et al: Retrodifferentiation of human tumor hepatocytes to stem cells leads to metabolic reprogramming and chemoresistance. Cancer Res. 79:1869–1883. 2019. View Article : Google Scholar : PubMed/NCBI
9	Choiniere J, Wu J and Wang L: Pyruvate dehydrogenase kinase 4 deficiency results in expedited cellular proliferation through E2F1-mediated increase of cyclins. Mol Pharmacol. 91:189–196. 2017. View Article : Google Scholar :
10	Dai Y, Xiong X, Huang G, Liu J, Sheng S, Wang H and Qin W: Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels. PLoS One. 9:e929622014. View Article : Google Scholar : PubMed/NCBI
11	Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J, et al: ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 53:1055–1068. 2018.PubMed/NCBI
12	Saunier E, Benelli C and Bortoli S: The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int J Cancer. 138:809–817. 2016. View Article : Google Scholar
13	Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC and Harris AL; Tumor and Angiogenesis Research Group: Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia. 7:1–6. 2005. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Liu F, Ao P, Li X, Zheng H, Wu D, Zhang N, She J, Yuan J and Wu X: Correlation of PDK1 expression with clinico-pathologic features and prognosis of hepatocellular carcinoma. OncoTargets Ther. 9:5597–5602. 2016. View Article : Google Scholar
15	Battello N, Zimmer AD, Goebel C, Dong X, Behrmann I, Haan C, Hiller K and Wegner A: The role of HIF-1 in oncostatin M-dependent metabolic reprogramming of hepatic cells. Cancer Metab. 4:32016. View Article : Google Scholar : PubMed/NCBI
16	Zhang W, Su J, Xu H, Yu S, Liu Y, Zhang Y, Sun L, Yue Y and Zhou X: Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells. PLoS One. 12:e01796722017. View Article : Google Scholar : PubMed/NCBI
17	Chou TC: Drug combination studies and their synergy quantifi-cation using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
18	Rodea-Palomares I, Petre AL, Boltes K, Leganés F, Perdigón-Melón JA, Rosal R and Fernández-Piñas F: Application of the combination index (CI)-isobologram equation to study the toxicological interactions of lipid regulators in two aquatic bioluminescent organisms. Water Res. 44:427–438. 2010. View Article : Google Scholar
19	Xu H, Sun L, He Y, Yuan X, Niu J, Su J and Li D: Deficiency in IL-33/ST2 Axis Reshapes Mitochondrial Metabolism in Lipopolysaccharide-Stimulated Macrophages. Front Immunol. 10:1272019. View Article : Google Scholar : PubMed/NCBI
20	He Y, Meng H, Xu H, Fan L, Zhou Z, Xu B, Sun L and Gao Y: Regulation of integrated stress response sensitizes U87MG glioblastoma cells to temozolomide through the mitochondrial apoptosis pathway. Anat Rec (Hoboken). 301:1390–1397. 2018. View Article : Google Scholar
21	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
22	Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, Li G, Bi ZY, Bi YY, Gong FY, et al: Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 10:973–987. 2018. View Article : Google Scholar
23	Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, Chen L and Gu J: HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics. 16:269–275. 2018. View Article : Google Scholar : PubMed/NCBI
24	Emmanouilidi A and Falasca M: Targeting PDK1 for Chemosensitization of Cancer Cells. Cancers (Basel). 9:92017. View Article : Google Scholar
25	Liberti MV and Locasale JW: The warburg effect: How does it benefit cancer cells? Trends Biochem Sci. 41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zhang W, Zhang SL, Hu X and Tam KY: Targeting tumor metabolism for cancer treatment: is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol Sci. 11:1390–1400. 2015. View Article : Google Scholar : PubMed/NCBI
27	Bhattacharya B, Mohd Omar MF and Soong R: The Warburg effect and drug resistance. Br J Pharmacol. 173:970–979. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ngoi NYL, Eu JQ, Hirpara J, Wang L, Lim JSJ, Lee SC, Lim YC, Pervaiz S, Goh BC and Wong ALA: Targeting cell metabolism as cancer therapy. Antioxid Redox Signal. 32:285–308. 2020. View Article : Google Scholar
29	Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M and Lincet H: How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 38:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
30	Amoedo ND, Obre E and Rossignol R: Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. Biochim Biophys Acta Bioenerg. 1858:674–685. 2017. View Article : Google Scholar : PubMed/NCBI
31	Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY and Park JG: Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis. 30:2182–2192. 2009. View Article : Google Scholar : PubMed/NCBI
32	Guo W, Zhang Y, Chen T, Wang Y, Xue J, Zhang Y, Xiao W, Mo X and Lu Y: Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol. 137:65–72. 2011. View Article : Google Scholar
33	Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 101:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
34	Jeoung NH: Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers. Diabetes Metab J. 39:188–197. 2015. View Article : Google Scholar : PubMed/NCBI
35	Qin L, Tian Y, Yu Z, Shi D, Wang J, Zhang C, Peng R, Chen X, Liu C, Chen Y, et al: Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth. Oncotarget. 7:1395–1407. 2016. View Article : Google Scholar :
36	Wada M, Horinaka M, Yasuda S, Masuzawa M, Sakai T and Katoh N: PDK1 is a potential therapeutic target against angiosarcoma cells. J Dermatol Sci. 78:44–50. 2015. View Article : Google Scholar : PubMed/NCBI
37	Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, et al: JX06 Selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res. 75:4923–4936. 2015. View Article : Google Scholar : PubMed/NCBI
38	Tataranni T and Piccoli C: Dichloroacetate (DCA) and cancer: An overview towards clinical applications. Oxid Med Cell Longev. 2019:82010792019. View Article : Google Scholar : PubMed/NCBI
39	Stacpoole PW, Martyniuk CJ, James MO and Calcutt NA: Dichloroacetate-induced peripheral neuropathy. Int Rev Neurobiol. 145:211–238. 2019. View Article : Google Scholar : PubMed/NCBI
40	Stacpoole PW: The pharmacology of dichloroacetate. Metabolism. 38:1124–1144. 1989. View Article : Google Scholar : PubMed/NCBI
41	Lu X, Zhou D, Hou B, Liu QX, Chen Q, Deng XF, Yu ZB, Dai JG and Zheng H: Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer. Cancer Manag Res. 10:1231–1241. 2018. View Article : Google Scholar : PubMed/NCBI